CorMedix Inc
CRMD
View Detailed Chart
7.690USD
+0.340+4.63%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
602.50MMarket Cap
3.24P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+4.63%
5 Days
-0.90%
1 Month
-31.71%
6 Months
-35.65%
Year to Date
-33.88%
1 Year
-26.76%
View Detailed Chart
TradingKey Stock Score of CorMedix Inc
Currency: USD Updated: 2026-02-06Key Insights
CorMedix Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 58 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 16.14.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CorMedix Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
CorMedix Inc Highlights
StrengthsRisks
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 66363.08% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 43.47M.
Overvalued
The company’s latest PE is 3.24, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 43.86M shares, increasing 0.02% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 6.95K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.50.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
16.143
Target Price
+119.63%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
CorMedix Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
CorMedix Inc Info
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Ticker SymbolCRMD
CompanyCorMedix Inc
CEOTodisco (Joseph)
Websitehttps://cormedix.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69171.230
-798.900 (-1.14%)
282.580
+22.390 (+8.61%)
2058.200
+6.470 (+0.32%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
